Linde plc Ordinary Shares (LIN)vsVersamet Royalties Corporation Common Stock (VMET)
LIN
Linde plc Ordinary Shares
$515.25
-1.15%
BASIC MATERIALS · Cap: $236.08B
VMET
Versamet Royalties Corporation Common Stock
$9.13
+2.24%
BASIC MATERIALS · Cap: $926.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Linde plc Ordinary Shares generates 48749% more annual revenue ($36.24B vs $74.18M). VMET leads profitability with a 49.9% profit margin vs 19.3%. VMET trades at a lower P/E of 24.3x. VMET earns a higher WallStSmart Score of 60/100 (C+).
LIN
Buy54
out of 100
Grade: C-
VMET
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-61.9%
Fair Value
$318.30
Current Price
$515.25
$196.95 premium
Intrinsic value data unavailable for VMET.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 28.0%
Generating 1.8B in free cash flow
Keeps 50 of every $100 in revenue as profit
Strong operational efficiency at 58.0%
Revenue surging 391.9% year-over-year
Earnings expanding 2123.0% YoY
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 10.5%
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LIN
The strongest argument for LIN centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 19.3% and operating margin at 28.0%.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.
Bear Case : LIN
The primary concerns for LIN are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : VMET
The primary concerns for VMET are Market Cap, Altman Z-Score.
Key Dynamics to Monitor
LIN profiles as a mature stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 391.9% — sustainability is the question.
LIN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor SPECIALTY CHEMICALS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VMET scores higher overall (60/100 vs 54/100), backed by strong 49.9% margins and 391.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Linde plc Ordinary Shares
BASIC MATERIALS · SPECIALTY CHEMICALS · USA
Linde plc is a multinational chemical company. It is the largest industrial gas company by market share and revenue. It serves customers in the healthcare, petroleum refining, manufacturing, food, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, electronics and water treatment industries. The company's primary business is the manufacturing and distribution of atmospheric gases, including oxygen, nitrogen, argon, rare gases, and process gases, including carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene.
Visit Website →Versamet Royalties Corporation Common Stock
BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA
Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.
Compare with Other SPECIALTY CHEMICALS Stocks
Want to dig deeper into these stocks?